These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 28666800

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model.
    Shi L, Zhang Z, Li L, Hölscher C.
    Behav Brain Res; 2017 Jun 01; 327():65-74. PubMed ID: 28342971
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease.
    Liu W, Li Y, Jalewa J, Saunders-Wood T, Li L, Hölscher C.
    Eur J Pharmacol; 2015 Oct 15; 765():284-90. PubMed ID: 26302060
    [Abstract] [Full Text] [Related]

  • 27. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA, Bergmann NC, Knop FK.
    Diabetes Obes Metab; 2016 Sep 15; 18(9):847-54. PubMed ID: 27160961
    [Abstract] [Full Text] [Related]

  • 28. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors.
    Spielman LJ, Gibson DL, Klegeris A.
    Eur J Cell Biol; 2017 May 15; 96(3):240-253. PubMed ID: 28336086
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
    Tai J, Liu W, Li Y, Li L, Hölscher C.
    Brain Res; 2018 Jan 01; 1678():64-74. PubMed ID: 29050859
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease.
    Zhang Z, Shi M, Li Z, Ling Y, Zhai L, Yuan Y, Ma H, Hao L, Li Z, Zhang Z, Hölscher C.
    Parkinsons Dis; 2023 Jan 01; 2023():7427136. PubMed ID: 37791037
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH, Fabricius K, Barkholt P, Mikkelsen JD, Jelsing J, Pyke C, Knudsen LB, Vrang N.
    Brain Res; 2016 Sep 01; 1646():354-365. PubMed ID: 27233809
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Neuroprotective effects of liraglutide against inflammation through the AMPK/NF-κB pathway in a mouse model of Parkinson's disease.
    Cao B, Zhang Y, Chen J, Wu P, Dong Y, Wang Y.
    Metab Brain Dis; 2022 Feb 01; 37(2):451-462. PubMed ID: 34817756
    [Abstract] [Full Text] [Related]

  • 38. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.
    Ji C, Xue GF, Li G, Li D, Hölscher C.
    Rev Neurosci; 2016 Jan 01; 27(1):61-70. PubMed ID: 26351802
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.